Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis

A Phase 2, Multi-Center Study to Evaluate Three Doses of NGM282 Administered for 24 Weeks in Patients With Primary Biliary Cirrhosis (PBC) Who Have Completed Study 13-0103

The purpose of this study is to determine the safety, tolerability, and activity of extended treatment with NGM282 in patients with Primary Biliary Cirrhosis.

Inclusion Criteria:

• Completion of NGM 13-0103
• Males or females, between 18 and 75 years of age, inclusive
• PBC Diagnosis consistent with AASLD and EASL guidelines
• Stable dose of UDCA

Exclusion Criteria:

• Chronic liver disease of a non-PBC etiology
• Evidence of clinically significant hepatic decompensation